newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates

Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetini